We are live on ! Find out more
THRD

Third Harmonic Bio
THRD

Delisted

THRD was delisted on the 30th of July, 2025.

Back to rankings

40 hedge funds and large institutions have $673M invested in Third Harmonic Bio in 2022 Q3 according to their latest regulatory filings, with 40 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

91.67% more ownership

Funds ownership: 0% → 91.67% (+92%)

Holders
40
Holders Change
+40
Holders Change %
–
% of All Funds
0.69%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.05%
New
40
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AVLSA
Atlas Venture Life Science Advisors
Massachusetts
+$197M
2
O
OrbiMed
New York
+$104M
3
BI
BVF Inc
California
+$63.1M
4
RCM
RA Capital Management
Massachusetts
+$62.6M
5
GA
General Atlantic
New York
+$53.3M

Top Sellers

No sellers this quarter

THRD Hedge Fund Activity: Q3 2022 in Review

40 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Third Harmonic Bio (THRD) for Q3 2022, worth a combined $673M.

Buyers outnumbered sellers: 40 funds opened new THRD positions and 0 closed out — a net gain of 40 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Atlas Venture Life Science Advisors, opening a new position worth an estimated $197M.

  • 40 institutional investors held Third Harmonic Bio (THRD) as of Q3 2022, up from 0 in Q2 2022.
  • Funds reported $673M of Third Harmonic Bio stock for Q3 2022.
  • 40 funds opened new Third Harmonic Bio positions in Q3 2022 and 0 closed out, a net change of +40 holders.
  • The largest Third Harmonic Bio buyer in Q3 2022 was Atlas Venture Life Science Advisors, an estimated $197M added.

Based on aggregated 13F filings for Q3 2022.